Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer

Jinye Xie; Shan Xing; Hongbo Jiang; Jiaju Zhang; Daxiao Li; Shiqiong Niu; Zhijian Huang; Haofan Yin

iScience (Apr 2024)

Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer

Jinye Xie,
Shan Xing,
Hongbo Jiang,
Jiaju Zhang,
Daxiao Li,
Shiqiong Niu,
Zhijian Huang,
Haofan Yin

Affiliations

Jinye Xie: Department of Laboratory Medicine, Zhongshan City People’s Hospital, Zhongshan, Guangdong, China
Shan Xing: Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, Guangdong, China
Hongbo Jiang: Department of Clinical Laboratory, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China
Jiaju Zhang: Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Daxiao Li: Department of Ophtalmology and ENT, Shenzhen Longgang District Second People’s Hospital, Shenzhen, Guangdong, China
Shiqiong Niu: Department of Clinical Laboratory, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China; Corresponding author
Zhijian Huang: Department of Pathology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China; Corresponding author
Haofan Yin: Department of Laboratory Medicine, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China; Department of Clinical Laboratory, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China; Corresponding author

Journal volume & issue: Vol. 27, no. 4
p. 109612

Abstract

Read online

Summary: Extracellular vesicles (EVs) were promising circulating biomarkers for multiple diseases, but whether serum EVs-derived proteins could be used as a reliable tumor biomarker for colorectal cancer (CRC) remained inconclusive. In this study, we identified CXCL4 by a 4D data-independent acquisition-based quantitative proteomics assay of serum EVs-derived proteins in 40 individuals and subsequently analyzed serum EVs-derived CXCL4 levels by ELISA in 2 cohorts of 749 individuals. The results revealed that EVs-derived CXCL4 levels were dramatically elevated in CRC patients than in benign colorectal polyp patients or healthy controls (HC). Furthermore, receiver operating characteristic curves revealed that EVs-derived CXCL4 exhibited superior diagnostic performance with area under the curve of 0.948 in the training cohort. Additionally, CXCL4 could effectively distinguish CRC in stage I/II from HC. Notably, CRC patients with high levels of EVs-derived CXCL4 have shorter 2-year progression-free survival than those with low levels. Overall, our findings demonstrated that serum EVs-derived CXCL4 was a candidate diagnostic and prognostic biomarker for CRC.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords